Treatment of orbital myositis with adalimumab (Humira)

Alexa B Adams; Michael Kazim; Thomas J A Lehman

Treatment of orbital myositis with adalimumab (Humira)

J Rheumatol. 2005 Jul;32(7):1374-5.

Authors

Alexa B Adams¹, Michael Kazim, Thomas J A Lehman

Affiliation

¹ Division of Pediatric Rheumatology, Hospital for Special Surgery, New York, New York 10021, USA.

PMID: 15996084

Abstract

Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.

Publication types

Case Reports

MeSH terms

Adalimumab
Adolescent
Adrenal Cortex Hormones / administration & dosage
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Drug Therapy, Combination
Female
Humans
Orbital Pseudotumor / drug therapy*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / immunology

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
Adalimumab